Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts

Feb 15 2019

• By Brenda Sandburg

Superbug strain bacteria concept as a killer microbe shaped as a death skull face as a symbol for MRSA medical healthcare risk and antimicrobial health hazard as a 3D illustration on white. - Illustration

Related Content

"Site License" Reimbursement Model For Limited Use Antibacterials Being Explored By US FDA, CMS

Jul 31 2018

How To Spur Antibiotic Development? Higher Reimbursement, Govt. Funding Proposed By PCAST

Sep 19 2014

Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch

Oct 23 2018

Melinta: A Pure-Play Antibiotics Specialist Rises

Jan 23 2018

New Report Calls For Pushing And Pulling In Global Fight Against Superbugs

Jan 24 2018

Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out

Jun 27 2018

Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma

Nov 23 2018

REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry

Sep 12 2018

Antimicrobial Resistance: Billions Needed To Encourage New Drugs

Sep 22 2016

Related Companies

Melinta Therapeutics, Inc.

Amplyx Pharmaceuticals, Inc.

Entasis Therapeutics Holdings Inc.

Achaogen, Inc.

The Medicines Company

GSK plc

Merck & Co., Inc.

Pfizer Inc.

Additional Topics

Commercial Policy Infectious Diseases BioPharmaceutical

More from Anti-infective

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window